Dementia Drugs Market
Global dementia drugs market is estimated to be valued at USD 24.47 Bn in 2024 and is expected to exhibit a CAGR of 6.6% during the forecast period (2024-2031). Dementia drugs market growth is driven by rising cases of Alzheimer's and other forms of dementia worldwide. Dementia is a syndrome caused due to disorders that affect the brain, such as Alzheimer's disease or strokes. It is characterized by a gradual loss of cognitive functions like thinking, remembering and reasoning. Increasing awareness about diagnosis and availability of treatment options drive more people to seek medical help for dementia symptoms. Several pharmaceutical companies are investing heavily in research and development of effective drugs to slow down or stop the progression of dementia.
Market Dynamics
Dementia drugs market growth is primarily driven by rapidly aging global population, which increases the risk of neurodegenerative conditions. Rising healthcare expenditures in developing nations and intensive R&D efforts by biopharmaceutical firms further contribute to market expansion. However, high drug development costs, particularly due to the failure of many candidate molecules in late-stage trials and the complexity of these diseases, pose significant challenges. The recent approval of disease-modifying drugs that aim to impact disease etiology rather than merely alleviating symptoms presents substantial opportunities for manufacturers. Increased government support and funding for dementia research are encouraging market participants to innovate and develop new therapies. As the prevalence of dementia continues to rise, driven by demographic changes, the demand for effective treatments is expected to grow, positioning the market for significant advancements.
Key features of the study
- This report provides in-depth analysis of the global dementia drugs market, and provides market size (US$ Bn) and compound annual growth rate (CAGR%) for the forecast period (2024–2031), considering 2023 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global dementia drugs market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Biogen, Eisai Co., Ltd., Novartis AG, Cipla, H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd., Sun Pharmaceutical Industries Ltd., Viatris Inc., Mapi-Pharma Ltd., AbbVie, Inc., DAIICHI SANKYO COMPANY, LIMITED., and F. Hoffmann-La Roche Ltd
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- Global dementia drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global dementia drugs market
Market Segmentation
Table of Contents
*Browse 34 market data tables and 30 figures on 'Dementia Drugs Market' - Global forecast to 2031
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize Now
Credibility and Certifications
860519526
9001:2015
27001:2022
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
